Prof. Xianghua Wu 吴向华
Chief Physician, Professor
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy and biological therapy for malignant tumors, with a focus on lung cancer and lymphoma.
Dr. Wu holds an MD and has worked in medical oncology at Fudan University Shanghai Cancer Center since 2004. Dr. Wu earned degrees from Jinan University and Fudan University. Research interests include chemotherapy, immune gene therapy, and combined chemo-immunotherapy for preventing tumor recurrence and metastasis. Dr. Wu has led multiple research grants and holds two national invention patents.
Professional roles
- Standing Committee Member, China Medical Education Association
- Member, Thoracic Oncology Professional Committee, Shanghai Anti-Cancer Association
- Standing Committee Member, Immunotherapy Committee, Shanghai Anti-Cancer Association
- Member, Clinical Oncology Collaboration Professional Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Wu Xianghua). Papers usually list the name as Xianghua Wu or Wu X.
Selected publications
64 papers on PubMed matched by name and affiliation; 11 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Thorac Dis, 2024 (senior author): A novel neoadjuvant therapy for early-stage non-small cell lung cancer in a mouse model. PubMed 38505061
- J Immunol Res, 2022 (senior author): A Novel In Situ Dendritic Cell Vaccine Triggered by Rose Bengal Enhances Adaptive Antitumour Immunity. PubMed 35155685
- J Thorac Dis, 2020 (senior author): Development of a nomogram for preoperative prediction of lymph node metastasis in non-small cell lung cancer: a SEER-based study. PubMed 32802444
- J Cell Biochem, 2020 (senior author): Transcription factor RUNX3 promotes CD8(+) T cell recruitment by CCL3 and CCL20 in lung adenocarcinoma immune microenvironment. PubMed 31898342
- Curr Probl Cancer, 2019 (senior author): Effect of clinicopathologic features on survival of patients with thymic carcinomas and thymic neuroendocrine tumors: A population-based analysis. PubMed 30952367
- J Transl Med, 2019 (senior author): Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinoma. PubMed 30832680
- J Cancer Res Clin Oncol, 2019 (senior author): Impact of the homogeneous and heterogeneous risk factors on the incidence and survival outcome of bone metastasis in NSCLC patients. PubMed 30603904
- J Cancer Res Clin Oncol, 2018 (senior author): Protective immunity elicited by measles vaccine exerts anti-tumor effects on measles virus hemagglutinin gene-modified cancer cells in a mouse model. PubMed 30090962
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion